SUMOylation of IGF2BP2 Promotes Vasculogenic Mimicry of Glioma Via Regulating OIP5-AS1/miR-495-3p

Hao Li
Shengjing Hospital of China Medical University

Di Wang
Shengjing Hospital of China Medical University

Bolong Yi
Shengjing Hospital of China Medical University

Heng Cai
Shengjing Hospital of China Medical University

Yipeng Wang
Shengjing Hospital of China Medical University

Xin Lou
Shengjing Hospital of China Medical University

Zhuo Xi
Shengjing Hospital of China Medical University

Zhen Li (lizhen7108_cmu@163.com)
Shengjing Hospital of China Medical University

Research

Keywords: SUMOylation, IGF2BP2, OIP5-AS1, miR-495-3p, vasculogenic mimicry, Glioma

DOI: https://doi.org/10.21203/rs.3.rs-152465/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: Glioma is the most common primary malignant tumor of human central nervous system, and its rich vascular characteristics make anti-angiogenic therapy become a therapeutic hotspot. However, the existence of glioma VM makes the anti-angiogenic therapy ineffective. SUMOylation is a post-translational modification that affects cell tumorigenicity by regulating the expression and activity of substrate proteins.

Methods: The binding and modification of IGF2BP2 and SUMO1 were identified using Ni\textsuperscript{2+}-NTA agarose bead pull-down assays, CO-IP and western blot; and in vitro SUMOylation assays combined with immunoprecipitation and Immunofluorescence staining were performed to explore the detail affects and regulations of the SUMOylation on IGF2BP2. RT-PCR and western blot were used to detect the expression levels of IGF2BP2, OIP5-AS1, and miR-495-3p in glioma tissues and cell lines. CCK-8 assays, cell transwell assays, and three-dimensional cell culture methods were used for evaluating the function of IGF2BP2, OIP5-AS1, miR-495-3p, HIF1A and MMP14 in biological behaviors of glioma cells. Meantime, RIP and luciferase reporter assays were used for inquiring into the interactions among IGF2BP2, OIP5-AS1, miR-495-3p, HIF1A and MMP14. Eventually, the tumor xenografts in nude mice further ascertained the effects of IGF2BP2 SUMOylation on glioma cells.

Results: This study proved that IGF2BP2 mainly binds to SUMO1 and was SUMOylated at the lysine residues K497, K505 and K509 sites, which can be reduced by SENP1. SUMOylation increased IGF2BP2 protein expression and blocked its degradation through ubiquitin-proteasome pathway, thereby increasing its stability. The expressions of IGF2BP2 and OIP5-AS1 were up-regulated and the expression of miR-495-3p was down-regulated in both glioma tissues and cells. IGF2BP2 enhances the stability of OIP5-AS1, thereby increasing the binding of OIP5-AS1 to miR-495-3p, weakening the binding of miR-495-3p to the 3'UTR of HIF1A and MMP14 mRNA, and ultimately promoting the formation of VM in glioma.

Conclusions: This study first revealed that SUMOylation of IGF2BP2 regulated OIP5-AS1/miR-495-3p to promote VM formation in glioma cells and xenografts growth in nude mice, providing a new idea for molecular targeted therapy of glioma.

Background

Glioma accounts for about 80% of human primary brain tumors, which is the most common central nervous system tumor(1). The characteristics of high recurrence rate make the average median survival period of glioma patients only about 12-15 months(2). Ascribable to the rich vascularity of glioma, anti-angiogenic therapy has become a new treatment scheme which has attracted much attentions. However, this treatment scheme does not significantly improve the survival rate of patients (3). The reason may be the angiogenesis mimicry (VM) in glioma, which is a tubular structure formatted by highly plastic multipotent malignant tumor cells. This special microcirculation system provides blood supply for tumors and involved in the migration and invasion of tumor cells (4, 5). Many studies have demonstrated that
VM is widely existed in various types of malignant tumors such as human gastric cancer, non-small cell lung cancer, melanoma, liver cancer, and glioma (6-10). In glioma, VM has closely correlation with the pathological grade, proliferation, migration and invasion of tumor (11, 12).

SUMOylation is one of the post-translational modifications (PTM) of proteins, which is participated in the regulation of multiple pivotal biological functions and has closely correlation with the tumorigenesis and development of the tumors(13-16). The essence of SUMOylation is a biological modification process of small molecule ubiquitin-like modifier (SUMO) attached to the protein substrate. The main form of SUMOylation is the binding of SUMO molecules to the receptor lysine residue of the target protein, and the substrate modification is gradually carried out through three enzymatic cascade steps [including the activation of heterodimer E1 enzyme (SAE1 and SAE2/UBA2) involved, the conjugation of E2 enzyme Ubc9-mediated and substrate modification through the co-operation of the E2, E3 protein ligases], thereby regulating the structure and function of the substrate protein. In addition, SUMOylation is a dynamic and reversible process. SUMO-specific proteases (SENPs) can specifically de-SUMOylated the substrate protein, and cooperate with SUMO molecules to regulate the SUMOylation state of the substrate protein, thereby regulating cell function(14, 17). Many studies have shown that SUMOylation may affect the expression, stability and subcellular localization of substrate proteins(18, 19), but its regulatory mechanism in tumorigenesis is still unclear.

Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2), one member of the IGF2 mRNA-binding protein family, is encoded by the IGF2BP2 gene which located on chromosome 3q27.2 (20). It plays an essential role in regulating subcellular mRNA localization, stability and translation (21, 22). Extensive studies have shown that IGF2BP2 is participated in regulating tumorigenesis. For example, in pancreatic cancer, up-regulation of IGF2BP2 promotes tumor cell proliferation by involved the PI3K/Akt signaling pathway activation(23). Overexpression of IGF2BP2 promotes the progression of pancreatic cancer cells, which can be treated as a marker for the diagnosis and prognosis of pancreatic cancer (24). In the nervous system, knockdown of IGF2BP2 can significantly reduce FBXL19-AS1 and tight junction related proteins expression, and then promote the permeability of blood-tumour barrier viaSTAU1-mediated mRNA decay negatively regulating ZNF765 expression(25). At present, the study of IGF2BP2 on VM of glioma has not been reported.

LncRNAs are a class of non-coding RNA with limited coding protein capability which length are more than 200 nucleotides. It plays an essential role in regulating tumorigenesis and development of the tumors(26). Current study has shown that OIP5-AS1 was up-regulated in breast cancer which regulates the expression of ZEB2 by acting as competitive endogenous RNA (ceRNA) for miR-340-5p, and then promotes metastasis of breast cancer(27). Similarly, OIP5-AS1 regulated ovarian cancer progression via miR-137/ZNF217 axis (28). Knockdown of OIP5-AS1 up-regulates miR-410 to specifically block Wnt-7b/β-catenin pathway, thereby inhibiting the growth, invasion and migration of glioma cells, and promoting their apoptosis (29). However, the effects of OIP5-AS1 on the VM formation ability of glioma cells, remain unclear.
miRNAs, a class of endogenous small non-coding RNAs with a length of about 20-22 bps, which are mainly participated in the post-transcriptional gene expression regulation by binding to the 3'UTR of the target gene, causing the degradation or inhibition of mRNAs, and thus playing an important role in the regulation of cell development, proliferation, apoptosis and differentiation (30, 31). MiR-495-3p is a key regulator of tumorigenesis and malignant progression which expression is dysregulated in varieties of tumors. miR-495-3p expression in prostate cancer is down-regulated, and the expression of TRIP13 is regulated by competitive combination with NORAD, which affects the proliferation, migration, invasion and apoptosis of tumor (32). miR-495-3p inhibits tumor cell proliferation, migration and invasion by targeting CTRP3 in osteosarcoma (33). In glioma, LGMN acts as a sponge of miR-495-3p through ceRNA mechanism to promote tumor progression (34). Nevertheless, the regulation mechanism of miR-495-3p in VM capacity of glioma still unclear.

HIF1A is one of the HIF complexes, which plays a crucial role in regulating oxygen homeostasis in physiological and pathological environment. HIF1A has been confirmed to be involved in the formation of VM in colorectal cancer and salivary adenoid cystic carcinoma, and has become a marker protein of VM and indicated poor prognosis of tumor (35, 36).

Matrix metalloproteinase 14 (MMP14) belongs to the family of metalloproteinases that degrade extracellular matrix. Recent studies have shown that MMP14 is one of VM marker proteins which positively correlated with VM formation in lung cancer and glioma (11, 37). In glioma, whether miR-495-3p regulates the expression of HIF1A and MMP14 or the formation of VM has not been reported.

In this study, we found that K497/505/509R was the main SUMOylation site of IGF2BP2, which could be SUMOylated mainly combined with SUMO1 and be de-SUMOylated by SENP1. SUMOylation can increase the expression of IGF2BP2 protein, block its degradation and then increase its stability, but has no effect on subcellular localization of IGF2BP2. The mutation of SUMOylation site significantly inhibited the SUMOylation of IGF2BP2, thereby reducing the VM capacity of glioma cells. We further detected the endogenous expression levels of IGF2BP2, OIP5-AS1, and miR-495-3p in both glioma tissues and cells, and further explored the mutual regulatory mechanism between these molecules and their effects on VM capacity of glioma cells. SUMOylation increased the expression and stability of IGF2BP2, and further promoted VM capacity of glioma cells via OIP5-AS1/miR-495-3p axis. In vivo experiments also confirmed that SUMOylation promoted the growth of xenograft tumors in nude mice. This study intends to provide new evidence for revealing the mechanism of glioma pathogenesis and development, and to find new targets for glioma molecular therapy.

**Methods**

**Pathological tissue specimens and cell culture**

The human glioma tissues and normal brain tissues involved in this experiment were obtained from the Department of Neurosurgery of Shengjing Hospital affiliated of China Medical University. All patients signed the informed consent form voluntarily. This research has already approved by the ethics
committee of Shengjing Hospital affiliated of China Medical University. The cells (HEK293T, U87, U251 and HA cells) involved in this experiment were purchased from the biotechnology company (Shanghai Gene Chemistry Co., Ltd, and Shanghai Zeye Biotechnology). More details of storage and cell culture, please refer to online Additional Materials and Methods.

**Reverse transcription and qRT-PCR**

Quantitative real-time PCR (qRT-PCR) was used to determine the RNA expression of each indicator in this study. The RNA of tissues and cells were extracted by Trizol reagent (Life Technologies Corporation, Carlsbad, CA, USA). The RNA expression of each indicator in this study was quantitatively analyzed by the 7500 Fast RTPCR System. More details refer to the Additional Materials and Methods.

**Western blot**

Western blot was used to detected the protein expression of each indicator in this study. More details refer to the Additional Materials and Methods.

**Cell transfection**

The indicate plasmids (overexpression, knockdown, or site-mutant) of each indicator was used to transfected different cells. Stable transfected and resistant cell clones were screened and established by G418, and Puromycin. More details refer to the Additional Materials and Methods.

**RNA binding protein immunoprecipitation assays**

The bounding between IGF2BP2 and OIP5-AS1 were detected by RNA binding protein immunoprecipitation (RIP) assays. More details refer to the Additional Materials and Methods.

**Ni\textsuperscript{2+}-NTA agarose beads pull-down assay**

SUMOylation of IGF2BP2 was analyzed in cells by using an in vivo SUMOylation assay with Ni\textsuperscript{2+}-NTA agarose beads. More details refer to the Additional Materials and Methods.

**Co-Immunoprecipitation (CO-IP)**

The binding and modification of endogenous SUMO1 on endogenous IGF2BP2 was detected by Co-IP. More details refer to the Additional Materials and Methods.

**Cell Counting Kit-8 (CCK-8) assay**

CCK-8 assays were used to evaluate the cell proliferation level in this study. More details refer to the Additional Materials and Methods.

**Cell Transwell method**
The ability for migration and invasion of glioma cells was detected by Transwell method in vitro. More details refer to the Additional Materials and Methods.

**Reporter vectors construction and luciferase reporter assays**

The responsive miR-495-3p binding sites in the OIP5-AS1, HIF1A 3’UTR and MMP14 3’UTR were determined by dual-luciferase reporter system. More vectors construction and experiment details refer to the Additional Materials and Methods.

**Tumor xenograft implantation in nude mice**

The stably transfected cells were constructed with indicated plasmids, and then xenografted into immunodeficient nude mice for in vivo experiment in this study. More details refer to the Additional Materials and Methods.

**Immunofluorescence staining**

The subcellular localization and expression of IGF2BP2 SUMOylated was detected by immunofluorescence staining in this study. More details refer to the Additional Materials and Methods.

**Cells VM formation assays**

Three-dimensional cell culture method was used to detect VM formation ability of glioma cells in vitro, Matrigel Basement Membrane Matrix (BD Biosciences, Bedford, MA, USA) was treated as medium in this study. More details refer to the Additional Materials and Methods.

**CD34 endothelial marker periodic Acid-Schiff dual staining (CD34-PAS)**

The qualitative and quantitative analyses of VM in tumor xenograft tissue sections of nude mice was detected by CD34-PAS assays. More details refer to the Additional Materials and Methods.

**Statistical analysis**

Data of this study were expressed as the mean ± standard deviation (SD) and were analyzed by GraphPad Prism 7.0 statistical software with the t-test or one-way ANOVA. Differences were considered statistically significant if P < 0.05.

**Result**

IGF2BP2 mainly combined with SUMO1 to form SUMO modification

In order to determine whether IGF2BP2 can be SUMOylated in cells, HA-IGF2BP2, His-SUMO1, His-SUMO2, His-SUMO3 and Flag-Ubc9 were respectively transfected into HEK293T cells. Ni²⁺-NTA agarose bead pull-down assays were used to pull down the His-SUMO conjugates for Western blotting. Our results showed
that IGF2BP2 could be modified by SUMO1, SUMO2 and SUMO3, and the modification by SUMO1 was the strongest (Fig. 1A). Therefore, the follow-up studies focused on the modification effect between IGF2BP2 and SUMO1.

SENP1 is one of the sumo specific proteases and participates in the process of SUMO modification. This study continues to verify the effect of SENP1 on SUMOylation of IGF2BP2. We transfected HA-IGF2BP2, His-SUMO1, Flag-Ubc9 and myc-SENP1 into HEK293T cells, respectively. Ni\(^{2+}\)-NTA agarose bead pull-down assays were used to verify if SENP1 can remove the SUMO1 modification. We found that Ubc9 significantly increased the SUMO1 modification of IGF2BP2, while SENP1 significantly decreased the modification effect above, which played a role of de-SUMOylation (Fig. 1B).

In addition, in this study, plasmid of SENP1 knockdown was stably transferred to HEK293T cells, and the SUMO1 modification of IGF2BP2 was further verified by Ni\(^{2+}\)-NTA agarose bead pull-down assays. Compared with NC group, the SUMOylation of IGF2BP2 in SENP1 (-) group was significantly enhanced (Fig. 1C).

His-SUMO1, Flag-Ubc9 with or without SENP1 were co-transfected into HEK293T cells. Ni\(^{2+}\)-NTA agarose bead pull-down assays were used to verify whether endogenous IGF2BP2 can combined with SUMO1 and be SUMOylated by SUMO1. The SUMOylation bands were detected by using anti-IGF2BP2 antibody, and SUMO1 modification was the best in the presence of Flag-Ubc9, but could almost be removed by SENP1 (Fig. 1D).

In this study, co-immunoprecipitation (CO-IP) was used to further verify the binding and modification of endogenous SUMO1 on endogenous IGF2BP2. First, HEK293T cells were stably transfected with knockdown SENP1, knockdown Ubc9 and sh-NC plasmid respectively, and then, the lysates were immunoprecipitated with SUMO1, IGF2BP2 or normal IgG antibodies. Finally, western blot was performed with anti-IGF2BP2 and anti-SUMO1 antibodies. The results showed that the endogenous SUMO1 could bind and modify the endogenous IGF2BP2 in HEK293T cells. The SUMOylation of IGF2BP2 was enhanced by SENP1 knockdown, while the SUMOylation of IGF2BP2 was significantly inhibited by Ubc9 knockdown. Compared with control group, input group confirmed that the knockdown of SENP1 and Ubc9 did not affect IGF2BP2 expression (Fig. 1E).

To further deepen understanding the mutual modification of endogenous IGF2BP2 and endogenous SUMO1 in cells. Lysates of U87 and U251 cells were used for IP with anti-SUMO1, anti-IGF2BP2 and anti-IgG antibodies, and then western blot was performed with anti-IGF2BP2 and anti-SUMO1 antibodies. The results indicated that endogenous IGF2BP2 could bind to endogenous SUMO1 in glioma cells (U87 and U251) and undergo SUMOylation (Fig. 1F-G)

**K497, k505 and k509 are the main SUMO-sites of IGF2BP2**

In order to determine the main SUMO-sites of IGF2BP2 in human, we predicted that lysines (Ks) at K497, k505 and k509 could be mutated to arginine (R) according to the analysis results of bioinformatics
software, and then as the main SUMO-sites for SUMOylation identification (Fig. 1H). We mutated the predicted lysins of IGF2BP2 protein, then co-transfected three single-lysin mutants and triple-lysin mutant with plasmids His-SUMO1 and Flag-Ubc9 into HEK293T cells for SUMO modification analysis by Ni²⁺-NTA agarose bead pull-down assays. The results indicated that compared with the wild-type (-Wt), the SUMO modification levels of IGF2BP2 were decreased in K497R, K505R, K509R and 3KR (K497/505/509R), and the SUMO modification level decreased most significantly in 3KR (K497/505/509R) (Fig. 1I).

**SUMO modification enhanced the stability of IGF2BP2, but did not affect its subcellular localization**

This study confirmed that SUMO modification could enhance the stability of IGF2BP2 by blocking the degradation process of IGF2BP2 in cells. First, the study found that there was no significant difference in the mRNA expression levels of IGF2BP2-Wt and IGF2BP2-3KR in HEK293T cells, but the protein expression level of IGF2BP2-3KR was significantly lower than that of IGF2BP2-Wt (Fig. 2A-B). Second, we co-transfected HA-IGF2BP2-Wt, HA-IGF2BP2-3KR, His-SUMO1 and myc-SENP1 into HEK293T cells, and used cycloheximide (CHX) to inhibit the synthesis of de novo proteins for 12 hours. We found that compared with the HA-IGF2BP2-Wt group alone, the expression level of IGF2BP2 protein in HA-IGF2BP2-Wt and His-SUMO1 co-transfected cells was significantly increased, but the protein expression enhancement effect was abolished when co-transfected with myc-SENP1 or HA-IGF2BP2-3KR (Fig. 2C). It is indicated that the degradation of IGF2BP2 was slowed down when conjugated with SUMO1. Third, the degradation of IGF2BP2 mainly occurs through ubiquitin proteasome pathway. Compared with chloroquine (lysosomal inhibitor), MG132 (proteasome inhibitor) significantly blocked IGF2BP2 degradation in the presence of CHX (Fig. 2D). Moreover, the degradation time of HA-IGF2BP2-3KR group was shorter than that of HA-IGF2BP2-wt group, and chloroquine did not block the degradation, while MG132 significantly blocked the degradation (Fig. 2D). Based on the above results, SUMOylation can effectively protect the substrate protein IGF2BP2 from degradation by ubiquitin proteasome pathway, thereby enhancing its stability.

In order to estimate if SUMOylation affects the subcellular localization of IGF2BP2, we co-transfected HA-IGF2BP2, His-SUMO1, Flag-Ubc9 and myc-SENP1 into HEK293T cells, and then the cytoplasmic and nuclear proteins were separated and extracted. Finally, the expression of IGF2BP2 protein was detected by western blot. The results showed that IGF2BP2 was mainly located in the cytoplasm, and SUMOylation did not affect the subcellular localization of IGF2BP2 (Fig. 2E). In this study, IGF2BP2-Wt and IGF2BP2-3KR were transfected into U87 and U251 cells, and the effect of SUMO-sites mutation on the subcellular localization of IGF2BP2 was detected by cytoplasmic and nuclear fractionation and Immunofluorescence staining. The results showed that after transfection of IGF2BP2-Wt and IGF2BP2-3KR, IGF2BP2 was still mainly located in the cytoplasm (Fig. 2H-G).

**IGF2BP2 and OIP5-AS1 were highly expressed in both glioma tissues and cells. The SUMO-site mutants (IGF2BP2-3KR), knockdown of IGF2BP2 and OIP5-AS1 inhibited the VM of glioma cells**
Western blot was used to detect the expression of IGF2BP2 in glioma tissues and cells. The results showed that in comparison to the NBTs, IGF2BP2 expression in LGGTs and HGGTs were significantly increased, and the expression increased as the pathological grade level increased; while IGF2BP2 expression in U87 and U251 cells were significantly higher than that in HA cells (Fig. 3A-B). To further explore the potential mechanisms of IGF2BP2 SUMOylation in regulating VM and the function of IGF2BP2 in glioma cells. The SUMO-site mutates (IGF2BP2-3KR) and knockdown IGF2BP2 cells were constructed. In comparison to the IGF2BP2-Wt group, cell proliferation, migration, invasion and VM of IGF2BP2-3KR group were significantly decreased and the expression of VM related proteins HIF1A and MMP14 also inhibited. Similar to above results, in comparison to the IGF2BP2(-)-NC group, cell proliferation, migration, invasion and VM of IGF2BP2(-) group were significantly decreased and the expression of VM related proteins HIF1A and MMP14 also inhibited (Fig. 3C-F).

OIP5-AS1 expression in glioma tissues and cells were detected by qRT-PCR. As the results showed, OIP5-AS1 was overexpressed in glioma tissues than in NBTs, and the expression increased with the pathological grade level. While the expression of OIP5-AS1 in U87 and U251 were significantly higher than that in HA cells (Fig. 4A-B). To further analyze the function of OIP5-AS1 in glioma cells, knockdown and overexpression plasmids of OIP5-AS1 were transfected into U87 and U251 cells. In comparison to the OIP5-AS1(-)-NC group, cell proliferation, migration, invasion and VM of OIP5-AS1(-) group were significantly decreased and the expression of VM related proteins HIF1A and MMP14 also inhibited. On the contrary, cell proliferation, migration, invasion and VM of the OIP5-AS1(+) group were increased and the expression of VM related proteins HIF1A and MMP14 was also increased, by comparison to the OIP5-AS1(+) -NC group (Fig. 4C-F).

**IGF2BP2 promoted VM in glioma cells by stabilizing and upregulating OIP5-AS1**

This study further explored the effect of IGF2BP2 SUMOylated and IGF2BP2 knockdown on OIP5-AS1. The results revealed that OIP5-AS1 expression was significantly decreased by IGF2BP2 SUMOylated and knockdown (Fig. 5A). In order to define the relationship between IGF2BP2 and OIP5-AS1, RNA immunoprecipitation (RIP) assay was used to detect the direct binding between IGF2BP2 and OIP5-AS1. The results showed that OIP5-AS1 was significantly enriched in the anti-IGF2BP2 group by comparison to the anti-IgG group (Fig. 5B). Then, the regulation mechanism of IGF2BP2 knockdown on OIP5-AS1 was further elucidated by nascent RNA capture and mRNA stability assay. The results showed that IGF2BP2 knockdown did not affect nascent OIP5-AS1 but significantly reduced the half-life of OIP5-AS1 (Fig. 5C-D). Knockdown of IGF2BP2 and knockdown or overexpression of OIP5-AS1 plasmid co-transfection in U87 and U251 cells to further detect their functions in glioma. The results revealed that cell proliferation, migration, invasion, and VM of IGF2BP2(-) + OIP5-AS1(-) group were significantly decreased when compared with the IGF2BP2(-) + OIP5-AS1(-)-NC group. In comparison with the IGF2BP2(-) + OIP5-AS1(+) -NC group, in IGF2BP2(-) + OIP5-AS1(+) group, OIP5-AS1(+) reversed the inhibitory effect of IGF2BP2(-) on cell proliferation, migration, invasion, VM ability of glioma cells (Fig. 5E-G). Meantime, IGF2BP2 knockdown significantly inhibited HIF1A and MMP14 expression. Co-transfection of IGF2BP2 knockdown and OIP5-AS1 knockdown enhanced the inhibition effect caused by IGF2BP2 knockdown alone, while co-
transfection of IGF2BP2 knockdown and OIP5-AS1 overexpression rescued the suppression effect (Fig. 5H).

**MiR-495-3p were lowly expressed in both glioma tissues and cells, miR-495-3p agomir inhibited VM of glioma cells**

QRT-PCR was used to detect miR-495-3p expression in glioma tissues and cells. The results confirmed that miR-495-3p expression was significantly down-regulated in glioma tissues and glioma cells (U87 and U251) (Fig. 6A-B). Up- or down-regulating miR-495-3p to further explore the function of miR-495-3p in glioma cells. Cell proliferation, migration, invasion and VM of the agomir-495-3p group were significantly decreased, while the expression of VM related proteins HIF1A and MMP14 was inhibited. On the contrary, cell proliferation, migration, invasion and VM of the antagomir-495-3p group were significantly increased, meanwhile, the expression of VM related proteins HIF1A and MMP14 was increased (Fig. 6C-F).

**OIP5-AS1 targeted and negatively regulated miR-495-3p. Knockdown of OIP5-AS1 and overexpression of miR-495-3p inhibited VM of glioma cells**

QRT-PCR was used to detect miR-495-3p expression in glioma cells after OIP5-AS1 knocked-down. The results confirmed that miR-495-3p expression level was significantly down-regulated in OIP5-AS1(-) group (Fig. 7A). The potential binding site between OIP5-AS1 and miR-495-3p was predicted by the bioinformatics database (Starbase 2.0). Dual-luciferase Reporter Gene Assays results indicated that the relative luciferase activity of OIP5-AS1-Wt in the agomir-495-3p group was significantly lower than in the agomir-495-3p-NC group, while in the agomir-495-3p-NC or agomir-495-3p groups, the relative luciferase activity of OIP5-AS1-Mut did not significantly change (Fig. 7B-C). These results indicate that OIP5-AS1 targets miR-495-3p. To figure out if miR-495-3p affected the tumor suppressor function of glioma cells induced by OIP5-AS1 knockdown, U87 and U251 cells co-transfected with OIP5-AS1(-) and agomir-495-3p or antagomir-495-3p. The results indicated that in comparison to OIP5-AS1(-) NC + agomir-495-3p NC group, cell proliferation, migration, invasion and VM of OIP5-AS1(-)+agomir-495-3p group were significantly decreased. The expression of VM-associated proteins HIF1A and MMP14 were significantly reduced (Fig. 7D-G).

**MiR-495-3p inhibited the expression of HIF1A and MMP14 by directly binding their 3’UTR, thus inhibiting the VM of glioma cells**

Up- or down-regulated miR-495-3p expression level in glioma cells to evaluated the the mRNA expression of HIF1A by qRT-PCR. The results indicated that HIF1A expression was significantly decreased after miR-495-3p agomir, while was significantly increased after miR-495-3p antagonim (Fig. 8A). The HIF1A 3’UTR existed a direct binding site of miR-495-3p which was predicted by the bioinformatics database (Starbase 2.0). Dual-luciferase Reporter Gene Assays results revealed that the relative luciferase activity of HIF1A-Wt in the agomir-495-3p group was significantly lower than in the agomir-495-3p-NC group, while in the agomir-495-3p-NC or agomir-495-3p groups, the relative luciferase activity of OIP5-AS1-Mut did not significantly change (Fig. 8B-C). To figure out if HIF1A could reverse the tumorsuppression effects of miR-
495-3p on U87 and U251 cells, HIF1A (+) and agomir-495-3p were transfected into cells and evaluated the biological behaviors. We found that the HIF1A overexpression significantly increased cell proliferation, migration, invasion and VM of glioma cells, and reverse the tumor-suppressive effect of miR-495-3p up-regulated (Fig. 8D-F). Similarly, similar results were observed in detecting the interaction between MMP14 and miR-495-3p (Fig. 8G-L).

**The inhibition of SUMOylation of IGF2BP2 could inhibit tumor xenograft growth, prolong the survival time and yield the lowest VM formation of nude mice**

The function of IGF2BP2 SUMOylation on glioma cells was further determined by using the subcutaneous and orthotopic transplantation model. As the results presented, in comparison to IGF2BP2-Wt group, the tumor volumes were significantly lower in IGF2BP2-3KR group (Fig. 9A-B). In addition, survival analysis showed that nude mice in IGF2BP2-Wt group have a longer survival time than in the IGF2BP2-3KR group (Fig. 9C). Last, the CD34-PAS dual-staining was used to detect the VM in different groups. The VM density in IGF2BP2-3KR group was lower than that in IGF2BP2-Wt group (Fig. 9D).

**Discussion**

SUMO protein, as the starting molecule of SUMOylation, initiates the process of SUMOylation by covalently binding with lysine residues of substrate protein. Numbers of studies have shown that SUMOylation can influence the stability, subcellular localization and protein activity of substrate protein, and then have a key impact on the development of tumor. For example, in non-small cell lung cancer, METTL3 combines with SUMO1 to make SUMO modification of METTL3 regulate its m6A RNA methyltransferase activity, resulting in the decrease of m6A level in mRNAs, and ultimately affect the growth of cell colonies and xenograft tumors (38). Slug protein interacts with Ubc9 and SUMO-1, and realizes SUMO modification in cells. Furthermore, more HDAC1 was recruited to enhance the transcriptional inhibitory activity of Slug, resulting in a decrease in the expression of target genes downstream of Slug, thereby promoting the metastasis of non-small cell lung cancer (39). In this study, we first found that IGF2BP2 was mainly combined with SUMO1 in cells and SUMOylation occurred. Subsequently, we verified the role of key enzymes (Ubc9 and SENP1) in promoting or de-SUMOylation in this process. Based on the prediction and analysis of GPS-SUMO (www.sumosp.biocuckoo.org/online.php), SUMOplot (www.abcepta.com/sumoplot), and JASSA (http://www.jassa.fr/index.php?m=jassa), the results of Ni²⁺-NTA agarose bead pull-down assays showed that IGF2BP2 combined with SUMO1 at K497, K505 and K509 sites, and SUMOylation of IGF2BP2 was inhibited more obviously when the three binding sites mutated together (3KR, K497/505/509R).

Numbers of studies had shown that SUMOylation plays an important role in regulating of substrate protein degradation (40, 41). To further clarify the effect of SUMOylation on IGF2BP2 expression, the study found that when the site mutation (3KR, K497/505/509R), the inhibited SUMO modification significantly reduced the translation level of IGF2BP2 protein but did not affect its mRNA transcription.
level. With the exist of CHX, the expression of IGF2BP2 increased which caused by SUMO1 overexpressed had indicated that its degradation was reduced, while SENP1 reversed the degradation process. However, the expression level of IGF2BP2-3KR was not significantly affected by SUMO1 and SENP1. The above results showed that SUMOylation increased the stability of IGF2BP2, but the inhibited SUMOylation after site mutation lost the enhancement effect on the stability of substrate protein. Further study on the degradation process of the substrate protein IGF2BP2 showed that the degradation speed of IGF2BP2-3KR was faster than that of IGF2BP2-Wt, and the degradation process could be blocked by MG132, rather than chloroquine. This indicated that IGF2BP2 was mainly degraded by ubiquitin-proteasome pathway, and the inhibited SUMOylation after site mutation could accelerate the degradation of substrate protein. Nucleoplasmic separation and immunofluorescence results showed that IGF2BP2 was mainly distributed in cytoplasm, the SUMOylation after site mutation did not affect the subcellular localization of IGF2BP2.

As a member of the IGF2 mRNA-binding protein family, IGF2BP2 acts a key role in a wide range of pathological and physiological functions such as embryonic development, neuronal differentiation, energy metabolism and tumorigenesis (42-45). Recent studies have shown that IGF2BP2 acts as oncogene in a variety of tumors. For example, high expression of IGF2BP2 in colon cancer cells, inhibited the expression of IGF2BP2 significantly inhibited the growth, invasion and migration of LoVo cells, and reduced the weight and microvessel density of tumor (46). IGF2BP2 alsoover-expressed in non-small cell lung cancer. Inhibition of IGF2BP2 expression significantly reduces cell proliferation and invasion of NSCLC cells, and IGF2BP2 overexpressed reverses the anti-tumor effects of miR-485-5p in tumor cells(47). In this study, western blot wasfound the high expression of IGF2BP2 in glioma tissues and cells, and IGF2BP2 expression level was positively correlated with pathological grade of glioma. IGF2BP2 knockdown significantly reducedcell proliferation, migration, invasion and VM formation of glioma cells. Meanwhile, SUMOylation of IGF2BP2 inhibited by site mutation significantly inhibited cell proliferation, migration, invasion and VM ability of glioma cells. The above results showed that IGF2BP2may play as an oncogene in glioma, SUMO modification of IGF2BP2promotes the formation of VM in glioma.

As a long-chain non-coding RNA, OIP5-AS1 plays an essential regulatory role in the development of tumors, and its regulatory role in cell proliferation, migration, invasion and other cellular functions has been confirmed. OIP5-AS1 is overexpressed in ovarian cancer, and overexpression of OIP5-AS1 as a molecular sponge adsorbs miR-34a to promote tumor cell migration and invasion (48). The expression of OIP5-AS1 was increased in pancreatic ductal adenocarcinoma. Overexpression of OIP5-AS1 increased FOXD1 expression and activated ERK pathway by targeting miR-429, which played a carcinogenic role in PDAC cells (49). In this study, we found that OIP5-AS1was over-expressed in both glioma tissues and cells. Knockdown of OIP5-AS1 significantly inhibited cell proliferation, migration, invasion and VM formation of glioma cells.

More and more studies have revealed that RBPs and IncRNAs binding and interacting with each other in a variety of tumors, RBPs up-regulate IncRNA expression by enhancing its the stability, and then regulate the occurrence and development of tumors (50, 51). For example, A1CF targets binding and increases the stability of FAM224A, thereby increasing the expression of FAM224A, then reducing the malignant
biological behavior of glioma (52). In this study, both SUMOylation and knockdown of IGF2BP2 can reduce the expression of OIP5-AS1. The RNA-IP experiment verified the direct binding between IGF2BP2 and OIP5-AS1. Knockdown of IGF2BP2 did not affect the nascent OIP5-AS1, but significantly reduced the half-life of OIP5-AS1, indicating IGF2BP2 could up-regulate OIP5-AS1 expression level by enhancing its stability. Knockdown of IGF2BP2 and OIP5-AS1 significantly inhibited cell proliferation, migration, invasion and VM formation of glioma cells. OIP5-AS1 overexpression rescued the tumor suppressor effect after IGF2BP2 knockdown. The above results showed that IGF2BP2 could bind to OIP5-AS1 and promote the stability of OIP5-AS1 in glioma cells, thereby promoting the formation of glioma VM.

This study further confirmed that miR-495-3p expression was down-regulated in glioma tissues and cells, and its expression level decreased with the pathological grade increasing. Up-regulated of miR-495-3p expression can significantly inhibit cell proliferation, migration, invasion and VM formation of glioma cells, which indicated that miR-495-3p acted as a tumor suppressor gene in glioma. Consistent with our results, miR-495-3p also acts as an anti-tumor gene in ovarian cancer and interacts with LINC01133 to promote epithelial ovarian cancer metastasis by regulating TPD52 (53). miR-495-3p is low-expressed in gastric cancer, and SNHG10 promotes cell proliferation and migration of gastric cancer cells by targeting miR-495-3p regulating CTNNB1 (54).

LncRNA can regulate miRNAs through competitive endogenous RNA (ceRNA) mechanism and inhibit the regulation of miRNAs on downstream target genes, so it is called “miRNA sponge” (55, 56). For example, RP11-619L19.2 regulates the expression of CD164 and EMT through sponge adsorption of miR-1271-5p, and promotes the development of colon cancer (57). ADAMTS9-AS1 inhibits the invasion of breast carcinoma cells by regulating ZFP36 via sponging miR-513a-5p (58). In this study, we first found that knockdown of OIP5-AS1 could significantly up-regulate the expression of miR-495-3p. For further understanding the potential regulatory mechanism between OIP5-AS1 and miR-495-3p, we predicted the binding between OIP5-AS1 and miR-495-3p based on the database (starBase2.0) and Dual-luciferase Reporter Gene Assays. Knockdown of OIP5-AS1 and overexpression of miR-495-3p can significantly inhibit cell proliferation, migration, invasion and VM capability of glioma cells. The above results show that inhibiting the expression of OIP5-AS1 can up-regulate the expression of miR-495-3p through competitive endogenous RNA mechanism, thereby inhibiting the proliferation, migration, invasion and VM capability of glioma cells.

Studies have shown that HIF1A and MMP14, as VM-related effector proteins, play the roles of oncogenes in a variety of tumors (11, 35-37). This study first found that knockdown or overexpression of miR-495-3p can significantly change HIF1A expression level in glioma cells. In order to further understand the potential regulatory mechanism between miR-495-3p and HIF1A, we predicted the binding between miR-495-3p and HIF1A based on the starBase2.0 database and dual-luciferase Reporter Gene Assays. Overexpression of HIF1A can rescued the inhibitory effect of miR-495-3p on the proliferation, migration, invasion and VM formation ability of glioma cells. Similar results were also observed in the verification of the regulatory mechanism between miR-495-3p and MMP14. The above results show that miR-495-3p
can target binding and regulate VM-related effector protein HIF1A and MMP14, thereby regulating the formation of VM in glioma.

Finally, the effect of SUMOylation of IGF2BP2 on the growth of xenografts in nude mice was verified in vitro. In comparison with IGF2BP2-Wt group, transplanted tumor size in IGF2BP2-3KR group was significantly reduced, whereas survival time of nude mice was significantly prolonged. The above results show that inhibit the SUMOylation of IGF2BP2 reduce glioma tumor growth also means IGF2BP2 SUMOylation has potential therapeutic value.

Conclusions

In summary, this study revealed for the first time that SUMOylation of IGF2BP2 promotes vasculogenic mimicry of glioma via regulating OIP5-AS1/miR-495-3p axis. We found that the expression of IGF2BP2 and OIP5-AS1 were up-regulated in glioma tissues and cells, while miR-495-3p was down-regulated. The SUMOylation of IGF2BP2 was mainly induced by the binding between IGF2BP2 and SUMO1. SUMO-site mutant (IGF2BP2-3KR) inhibited IGF2BP2 SUMOylation, resulting in accelerated degradation and decreased stability of IGF2BP2 and decreased the expression level of IGF2BP2 protein in cytoplasm. In addition, knockdown of IGF2BP2 reduced the stability and expression level of OIP5-AS1, thereby reducing the combination of OIP5-AS1 and miR-495-3p, enhancing the negative regulation of miR-495-3p on HIF1A and MMP14, and ultimately inhibiting the proliferation, migration, invasion and VM in glioma cells. The results of this study confirmed an important mechanism of IGF2BP2 SUMOylation in regulating VM of glioma. IGF2BP2, OIP5-AS1 and miR-495-3p may become new targets for molecular targeted therapy of glioma, and the research on the treatment of gliomas needs to be further studied.

Abbreviations

SUMO: Small molecule ubiquitin-like modifier, IGF2BP2: Insulin-like growth factor 2 mRNA-binding protein 2, SENPs: SUMO-specific proteases, PTM: post-translational modifications, OIP5-AS1: OIP5 antisense RNA 1, HIF1A: hypoxia inducible factor 1 subunit alpha, ceRNA: Competitive endogenous RNA, CHX: Cycloheximide, CCK-8: Cell Counting Kit-8, LncRNAs: Long non-coding RNAs, MMP14: Matrix metalloproteinase 14, NBTs: Normal brain tissues, LGGTs: Low grade glioma tissues, HGGTs: High grade glioma tissues, NHA: Normal human astrocyte, PAS: Periodic acid-schiff, qRT-PCR: Quantitative real-time PCR, RBPs: RNA-binding proteins, VM: vasculogenic mimicry;

Declarations

Acknowledgment

This work was supported by grants from the Natural Science Foundation of Liaoning Province (2018-ME-086), and outstanding scientific fund of Shengjing hospital (No. 2018M0167, 2018M0214, 2018Y17803).

Funding
This work was supported by grants from the Natural Science Foundation of Liaoning Province (2018-ME-086), and outstanding scientific fund of Shengjing hospital (No. 2018M0167, 2018M0214, 2018Y17803).

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Authors’ contribution**

Zhen Li, Heng Cai and Hao Li conceived and designed the study. Hao Li, Di Wang, Bolong Yi, Yipeng Wang, and Xin Lou contributed to carry out the experiments. Hao Li and Di Wang contributed to data analysis. Zhen Li and Zhuo Xi provided clinical samples and clinical information. Hao Li wrote the manuscript. Zhen Li revised the paper. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

This research had obtained approvals of Shengjing Hospital Ethical Committee and Administrative Panel on Laboratory Animal Care of the Shengjing Hospital.

**Consent for publication**

All authors have read and approve the manuscript publication in Journal of Experimental & Clinical Cancer Research.

**Competing Interests**

The authors have declared that no competing interest exists.

**References**

1. Lou J, Hao Y, Lin K, Lyu Y, Jin BJMC. Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis. 2020;19(1):138.

2. Khasraw M, Lassman ABJCOR. Advances in the Treatment of Malignant Gliomas. 2010;12(1):26-33.

3. Xu Y, Li Q, Li XY, Yang QY, Xu WW, Liu GLJJoE, et al. Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis. 2012;31(1):16.

4. Angara K, Borin TF, Arbab ASJTo. Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma. 2017;10(4):650.

5. Sun H, Zhang D, Yao Z, Lin X, Liu J, Gu Q, et al. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry. 2017:1-9.

6. Zhao J, Wu J, Qin Y, Zhang W, Huang G, Qin L. LncRNA PVT1 induces aggressive vasculogenic mimicry formation through activating the STAT3/Slug axis and epithelial-to-mesenchymal transition
7. Zhao B, Wu M, Hu Z, Ma Y, Qi W, Zhang Y, et al. Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation. Signal transduction and targeted therapy. 2020;5(1):117.

8. Lacal PM, Atzori MG, Ruffini F, Scimeca M, Bonanno E, Cicconi R, et al. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma. Pharmacological research. 2020;159:104957.

9. Huang XY, Huang ZL, Huang J, Xu B, Huang XY, Xu YH, et al. Exosomal circRNA-100338 promotes hepatocellular carcinoma metastasis via enhancing invasiveness and angiogenesis. Journal of experimental & clinical cancer research : CR. 2020;39(1):20.

10. Cai HP, Wang J, Xi SY, Ni XR, Chen YS, Yu YJ, et al. Tenascin-cmediated vasculogenic mimicry formation via regulation of MMP2/MMP9 in glioma. Cell Death Dis. 2019;10(12):879.

11. Guo J, Cai H, Liu X, Zheng J, Liu Y, Gong W, et al. Long Non-coding RNA LINC00339 Stimulates Glioma Vasculogenic Mimicry Formation by Regulating the miR-539-5p/TWIST1/MMPs Axis. Molecular therapy Nucleic acids. 2018;10:170-86.

12. Jing F, Ruan X, Liu X, Yang C, Wang D, Zheng J, et al. The PABPC5/HCG15/ZNF331 Feedback Loop Regulates Vasculogenic Mimicry of Glioma via STAU1-Mediated mRNA Decay. Molecular therapy oncolytics. 2020;17:216-31.

13. Liang Z, Yang Y, He Y, Yang P, Wang X, He G, et al. SUMOylation of IQGAP1 promotes the development of colorectal cancer. Cancer Lett. 2017;411:90-9.

14. Yang Y, He Y, Wang X, Liang Z, He G, Zhang P, et al. Protein SUMOylation modification and its associations with disease. Open biology. 2017;7(10).

15. Zhang A, Tao W, Zhai K, Fang X, Huang Z, Yu JS, et al. Protein Sumoylation with SUMO1 Promoted by Pin1 in Glioma Stem Cells Augments Glioblastoma Malignancy. Neuro Oncol. 2020.

16. Liu C, Peng Z, Li P, Fu H, Feng J, Zhang Y, et al. IncRNA RMST Suppressed GBM Cell Mitophagy through Enhancing FUS SUMOylation. Molecular therapy Nucleic acids. 2020;19:1198-208.

17. Kessler BM, Bursomanno S, McGouran JF, Hickson ID, Liu Y. Biochemical and Mass Spectrometry-Based Approaches to Profile SUMOylation in Human Cells. Methods in molecular biology (Clifton, NJ). 2017;1491:131-44.

18. Zhu C, Chen C, Huang J, Zhang H, Zhao X, Deng R, et al. SUMOylation at K707 of DGCR8 controls direct function of primary microRNA. Nucleic Acids Res. 2015;43(16):7945-60.

19. Zhu C, Chen C, Chen R, Deng R, Zhao X, Zhang H, et al. K259-SUMOylation of DGCR8 promoted by p14ARF exerts a tumor-suppressive function. Journal of molecular cell biology. 2016;8(5):456-8.

20. Chou CH, Chang CY, Lu HJ, Hsin MC, Chen MK, Huang HC, et al. IGF2BP2 Polymorphisms Are Associated with Clinical Characteristics and Development of Oral Cancer. Int J Mol Sci. 2020;21(16).
21. Bell JL, Wächter K, Mühleck B, Pazaitis N, Köhn M, Lederer M, et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? Cell Mol Life Sci. 2013;70(15):2657-75.

22. Christiansen J, Kolte AM, Hansen T, Nielsen FC. IGF2 mRNA-binding protein 2: biological function and putative role in type 2 diabetes. Journal of molecular endocrinology. 2009;43(5):187-95.

23. Xu X, Yu Y, Zong K, Lv P, Gu Y. Up-regulation of IGF2BP2 by multiple mechanisms in pancreatic cancer promotes cancer proliferation by activating the PI3K/Akt signaling pathway. Journal of experimental & clinical cancer research : CR. 2019;38(1):497.

24. Dahlem C, Barghash A, Puchas P, Haybaeck J, Kessler SM. The Insulin-Like Growth Factor 2 mRNA Binding Protein IMP2/IGF2BP2 is Overexpressed and Correlates with Poor Survival in Pancreatic Cancer. Int J Mol Sci. 2019;20(13).

25. Liu X, Wu P, Su R, Xue Y, Yang C, Wang D, et al. IGF2BP2 stabilized FBXL19-AS1 regulates the blood-tumour barrier permeability by negatively regulating ZNF765 by STAU1-mediated mRNA decay. RNA biology. 2020:1-12.

26. Liu X, Feng S, Zhang XD, Li J, Zhang K, Wu M, et al. Non-coding RNAs, metabolic stress and adaptive mechanisms in cancer. Cancer Lett. 2020;491:60-9.

27. Meng L, Yue X, Zhou D, Li H. Long non coding RNA OIP5-AS1 promotes metastasis of breast cancer via miR-340-5p/ZEB2 axis. Oncology reports. 2020;44(4):1662-70.

28. Guo L, Chen J, Liu D, Liu L. OIP5-AS1/miR-137/ZNF217 Axis Promotes Malignant Behaviors in Epithelial Ovarian Cancer. Cancer management and research. 2020;12:6707-17.

29. Sun WL, Kang T, Wang YY, Sun JP, Li C, Liu HJ, et al. Long noncoding RNA OIP5-AS1 targets Wnt-7b to affect glioma progression via modulation of miR-410. Biosci Rep. 2019;39(1).

30. Stark A, Brennecke J, Bushati N, Russell RB, Cohen SM. Animal MicroRNAs confer robustness to gene expression and have a significant impact on 3'UTR evolution. Cell. 2005;123(6):1133-46.

31. Ge X, Gong L. MiR-590-3p suppresses hepatocellular carcinoma growth by targeting TEAD1. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2017;39(3):1010428317695947.

32. Chen F, Liu L, Wang S. Long non-coding RNA NORAD exhaustion represses prostate cancer progression through inhibiting TRIP13 expression via competitively binding to miR-495-3p. Cancer cell international. 2020;20:323.

33. Zhao G, Zhang L, Qian D, Sun Y, Liu W. miR-495-3p inhibits the cell proliferation, invasion and migration of osteosarcoma by targeting C1q/TNF-related protein 3. Onco Targets Ther. 2019;12:6133-43.

34. Liao K, Qian Z, Zhang S, Chen B, Li Z, Huang R, et al. The LGMN pseudogene promotes tumor progression by acting as a miR-495-3p sponge in glioblastoma. Cancer Lett. 2020;490:111-23.

35. Li W, Zong S, Shi Q, Li H, Xu J, Hou F. Hypoxia-induced vasculogenic mimicry formation in human colorectal cancer cells: Involvement of HIF-1α, Claudin-4, and E-cadherin and Vimentin. Sci Rep. 2016;6:37534.
36. Wang HF, Wang SS, Zheng M, Dai LL, Wang K, Gao XL, et al. Hypoxia promotes vasculogenic mimicry formation by vascular endothelial growth factor A mediating epithelial-mesenchymal transition in salivary adenoid cystic carcinoma. Cell Prolif. 2019;52(3):e12600.

37. Zhang Z, Nong L, Chen M, Gu X, Zhao W, Liu M, et al. Baicalein suppresses vasculogenic mimicry through inhibiting RhoA/ROCK expression in lung cancer A549 cell line. Acta biochimica et biophysica Sinica. 2020;52(9):1007-15.

38. Du Y, Hou G, Zhang H, Dou J, He J, Guo Y, et al. SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function. Nucleic Acids Res. 2018;46(10):5195-208.

39. Hung PF, Hong TM, Chang CC, Hung CL, Hsu YL, Chang YL, et al. Hypoxia-induced Slug SUMOylation enhances lung cancer metastasis. Journal of experimental & clinical cancer research : CR. 2019;38(1):5.

40. Gareau JR, Lima CD. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nature reviews Molecular cell biology. 2010;11(12):861-71.

41. Geiss-Friedlander R, Melchior F. Concepts in sumoylation: a decade on. Nature reviews Molecular cell biology. 2007;8(12):947-56.

42. Liu HB, Muhammad T, Guo Y, Li MJ, Sha QQ, Zhang CX, et al. RNA-Binding Protein IGF2BP2/IMP2 is a Critical Maternal Activator in Early Zygotic Genome Activation. Advanced science (Weinheim, Baden-Württemberg, Germany). 2019;6(15):1900295.

43. Fujii Y, Kishi Y, Gotoh Y. IMP2 regulates differentiation potentials of mouse neocortical neural precursor cells. Genes to cells : devoted to molecular & cellular mechanisms. 2013;18(2):79-89.

44. Janiszewska M, Suvà ML, Riggi N, Houtkooper RH, Auwerx J, Clément-Schatlo V, et al. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev. 2012;26(17):1926-44.

45. Cao J, Mu Q, Huang H. The Roles of Insulin-Like Growth Factor 2 mRNA-Binding Protein 2 in Cancer and Cancer Stem Cells. Stem cells international. 2018;2018:4217259.

46. Wu XL, Lu RY, Wang LK, Wang YY, Dai YJ, Wang CY, et al. Long noncoding RNA HOTAIR silencing inhibits invasion and proliferation of human colon cancer LoVo cells via regulating IGF2BP2. J Cell Biochem. 2018.

47. Huang RS, Zheng YL, Li C, Ding C, Xu C, Zhao J. MicroRNA-485-5p suppresses growth and metastasis in non-small cell lung cancer cells by targeting IGF2BP2. Life Sci. 2018;199:104-11.

48. Jiang X, Ye Z, Jiang Y, Yu W, Fang Q. LncRNA OIP5-AS1 upregulates snail expression by sponging miR-34a to promote ovarian carcinoma cell invasion and migration. Biological research. 2020;53(1):49.

49. Wu L, Liu Y, Guo C, Shao Y. LncRNA OIP5-AS1 promotes the malignancy of pancreatic ductal adenocarcinoma via regulating miR-429/FOXD1/ERK pathway. Cancer cell international. 2020;20:296.

50. Xu CZ, Jiang C, Wu Q, Liu L, Yan X, Shi R. A Feed-Forward Regulatory Loop between HuR and the Long Noncoding RNA HOTAIR Promotes Head and Neck Squamous Cell Carcinoma Progression and
Metastasis. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2016;40(5):1039-51.

51. Chai Y, Liu J, Zhang Z, Liu L. HuR-regulated lncRNA NEAT1 stability in tumorigenesis and progression of ovarian cancer. Cancer medicine. 2016;5(7):1588-98.

52. Song Y, Shao L, Xue Y, Ruan X, Liu X, Yang C, et al. Inhibition of the aberrant A1CF-FAM224A-miR-590-3p-ZNF143 positive feedback loop attenuated malignant biological behaviors of glioma cells. Journal of experimental & clinical cancer research : CR. 2019;38(1):248.

53. Liu S, Xi X. LINC01133 contribute to epithelial ovarian cancer metastasis by regulating miR-495-3p/TPD52 axis. Biochem Biophys Res Commun. 2020.

54. Yuan X, Yang T, Xu Y, Ou S, Shi P, Cao M, et al. SNHG10 Promotes Cell Proliferation and Migration in Gastric Cancer by Targeting miR-495-3p/CTNNB1 Axis. Digestive diseases and sciences. 2020.

55. Yoon JH, Abdelmohsen K, Gorospe M. Functional interactions among microRNAs and long noncoding RNAs. Seminars in cell & developmental biology. 2014;34:9-14.

56. Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505(7483):344-52.

57. Zhang XW, Li SL, Zhang D, Sun XL, Zhai HJ. RP11-619L19.2 promotes colon cancer development by regulating the miR-1271-5p/CD164 axis. Oncology reports. 2020;44(6):2419-28.

58. Fang S, Zhao Y, Hu X. LncRNA ADAMTS9-AS1 Restrains the Aggressive Traits of Breast Carcinoma Cells via Sponging miR-513a-5p. Cancer management and research. 2020;12:10693-703.

**Figures**
Figure 5

IGF2BP2 enhanced the biological behavior of glioma cells by Increasing the Stability of OIP5-AS1 (A) SUMOylation of IGF2BP2 and IGF2BP2 knockdown reduce the expression of OIP5-AS1. Data are expressed as the mean ± SD (n=3). **p<0.01, vs. IGF2BP2(-) NC. (B) Verifying the binding interaction between IGF2BP2 and OIP5-AS1. Data are expressed as the mean ± SD (n=3). **p<0.01 vs. anti-normal IgG groups. (C) Knockdown of IGF2BP2 to detect nascent OIP5-AS1 in glioma cells (U87 and U251). Data
are expressed as the mean ± SD (n=3). (D) The effect of IGF2BP2 knockdown on OIP5-AS1 half-life. Data are expressed as mean ± SD (n=3). **p<0.01, vs. IGF2BP2(-) NC. (E-G) CCK-8 assay, cell transwell assay, and three-dimensional cell culture method were used to detect the effects of knockdown of IGF2BP2, knockdown and overexpression of OIP5-AS1 on proliferation, migration, invasion and VM formation. *p<0.05, **p<0.01, vs. IGF2BP2(-) + OIP5-AS1(-) NC. ##p<0.01, vs. IGF2BP2(-) + OIP5-AS1(+) NC. Scale bar=50μm. (H) Western blot was used to detected the protein expression levels of HIF1A and MMP14 in glioma cells (U87 and U251) after knockdown of IGF2BP2, knockdown and overexpression of OIP5-AS1. Data are presented as the mean ± SD (n=3), **p<0.01, ##p<0.01, vs. IGF2BP2(-).
Figure 7

MiR-495-3p target OIP5-AS1 and mediate the inhibitory effects of OIP5-AS1 knockdown on glioma cells (A) RT-PCR was used to detect the expression of miR-495-3p after OIP5-AS1 knockdown. Data are presented as the mean ± SD (n=3), **P<0.01, vs. OIP5-AS1(-) NC. (B-C) Predicted the binding sites of miR-495-3p in OIP5-AS1-Wt sequence and the designed mutant sequence of miR-495-3p binding site (OIP5-AS1-Mut). Relative luciferase activity was detected after cells were transfected with OIP5-AS1-Wt or OIP5-
AS1-Mut. Data are presented as the mean ± SD (n=3). **P<0.01 vs agomir-495-3p-NC. (D-F) CCK-8 assay, cell transwell assay, and three-dimensional cell culture method were used to detect the effects of OIP5-AS1 and mir-495-3p on proliferation, migration, invasion and VM formation. Data are presented as the mean ± SD (n=3), **P<0.01, vs. OIP5-AS1(-)-NC+agomir-495-3p-NC. Scale bar=50 μm. (G) Western blot was used to detected the effects of OIP5-AS1 and mir-495-3p on the protein expression levels of HIF1A and MMP14 in glioma cells (U87 and U251). Data are presented as the mean ± SD (n=3), **P<0.01, vs. OIP5-AS1(-)-NC+agomir-495-3p-NC.